1. Boston Scientific will hold a Q2 financial results webcast on July 23. 2. The event will be led by CEO Mike Mahoney and CFO Jon Monson. 3. A news release with financial results will precede the conference call.
The upcoming financial results may not significantly alter BSX’s stock price based on prior performance. Historical releases have shown mixed reactions in the market.
The earnings call is significant for investor sentiment but may not drive drastic changes without major surprises.
The immediate financial results will impact market perception and potentially influence stock price in the short term.
/PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2025, on Wednesday, July 23, 2025, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the second quarter on July 23 prior to the conference call.
A live webcast and replay for the event will be accessible at https://investors.bostonscientific.com. The replay will be available approximately one hour following the completion of the event.
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and connect on LinkedIn and X.
Chanel Hastings
Media Relations
+1 (508) 382-0288
[email protected]
Lauren Tengler
Investor Relations
+1 (508) 683-4479
[email protected]
SOURCE Boston Scientific Corporation